Compass Therapeutics (NASDAQ:CMPX) Posts Earnings Results

Compass Therapeutics (NASDAQ:CMPX) announced its earnings results on Wednesday. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.06, Zacks reports.

Compass Therapeutics Price Performance

Shares of CMPX stock traded up $0.18 on Friday, hitting $4.18. 1,264,281 shares of the company’s stock were exchanged, compared to its average volume of 1,450,805. The company has a 50 day moving average of $3.76 and a 200 day moving average of $2.96. The stock has a market cap of $577.32 million, a P/E ratio of -9.28 and a beta of 1.48. Compass Therapeutics has a 12 month low of $1.27 and a 12 month high of $4.86.

Analyst Ratings Changes

CMPX has been the topic of a number of analyst reports. Compass Point set a $10.00 price target on Compass Therapeutics in a research report on Monday, October 6th. D. Boral Capital reiterated a “buy” rating and set a $30.00 target price on shares of Compass Therapeutics in a research report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Wednesday, October 8th. Lifesci Capital initiated coverage on Compass Therapeutics in a research note on Monday, October 6th. They issued an “outperform” rating and a $10.00 price target for the company. Finally, Guggenheim increased their price objective on shares of Compass Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $12.90.

Institutional Investors Weigh In On Compass Therapeutics

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in shares of Compass Therapeutics by 45.6% during the 3rd quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company’s stock valued at $24,720,000 after purchasing an additional 2,212,794 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its position in Compass Therapeutics by 11.3% in the second quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company’s stock valued at $11,505,000 after buying an additional 449,868 shares in the last quarter. Invesco Ltd. grew its stake in shares of Compass Therapeutics by 58.1% during the second quarter. Invesco Ltd. now owns 58,735 shares of the company’s stock worth $153,000 after buying an additional 21,578 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Compass Therapeutics during the second quarter worth $84,000. Finally, Marex Group plc acquired a new position in shares of Compass Therapeutics during the second quarter worth $61,000. 68.43% of the stock is currently owned by institutional investors and hedge funds.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.